Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older

Gerardo Alvarez-Uria, Raghavakalyan Pakam, Praveen Kumar Naik, Manoranjan Midde, Gerardo Alvarez-Uria, Raghavakalyan Pakam, Praveen Kumar Naik, Manoranjan Midde

Abstract

Background: The World Health Organization recommends non-nucleoside reverse transcriptase inhibitors (NNRTIs)-based antiretroviral therapy (ART) for children three years and older. In younger children, starting ART with lopinavir boosted with ritonavir (LPVr) results in lower risk of virological failure, but data in children three years and older are scarce, and long-term ART with LPVr is problematic in resource-poor settings.

Methodology: Retrospective cohort of children three years and older who started triple ART including LPVr or a NNRTI between 2007 and 2013 in a rural setting in India. Children who started LPVr were switched to nevirapine-based ART after virological suppression. We analysed two outcomes, virological suppression (HIV-RNA <400 copies/ml) within one year of ART using logistic regression, and time to virological failure (HIV-RNA >1000 copies/ml) after virological suppression using Cox proportional hazard regression. A sensitivity analysis was performed using inverse probability of treatment weighting (IPTW) based of propensity score methods.

Findings: Of 325 children having a viral load during the first year of ART, 74/83 (89.2%) in the LPVr group achieved virological suppression versus 185/242 (76.5%) in the NNRTI group. In a multivariable analysis, the use of LPVr-based ART was associated with higher probability of virological suppression (adjusted odds ratio 3.19, 95% confidence interval [CI] 1.11-9.13). After IPTW, the estimated risk difference was 12.2% (95% CI, 2.9-21.5). In a multivariable analysis including 292 children who had virological suppression and available viral loads after one year of ART, children switched from LPVr to nevirapine did not have significant higher risk of virological failure (adjusted hazard ratio 1.18, 95% CI 0.36-3.81).

Conclusions: In a cohort of HIV infected children three years and older in a resource-limited setting, an LPVr induction- nevirapine maintenance strategy resulted in more initial virological suppression and similar incidence of virological failure after initial virological suppression than NNRTI-based regimens.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Proportion of children without virological…
Figure 1. Proportion of children without virological failure after initial virological suppression over time.
LPVr-NVP, ritonavir boosted lopinavir-based regimen followed by switch to nevirapine-based regimen; NNRTI, non-nucleoside reverse transcriptase inhibitor-based regimen.

References

    1. Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, et al. (2007) Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr 46: 187–193 10.1097/QAI.0b013e31814278c0
    1. Sigaloff KCE, Calis JCJ, Geelen SP, van Vugt M, de Wit TFR (2011) HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. Lancet Infect Dis 11: 769–779 10.1016/S1473-3099(11)70141-4
    1. Dlamini JN, Hu Z, Ledwaba J, Morris L, Maldarelli FM, et al. (2011) Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 58: 304–308 10.1097/QAI.0b013e3182278c29
    1. Lockman S, Hughes M, Sawe F, Zheng Y, McIntyre J, et al. (2012) Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med 9: e1001236 10.1371/journal.pmed.1001236
    1. Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, et al. (2012) Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 366: 2380–2389 10.1056/NEJMoa1113249
    1. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, et al. (2010) Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 363: 1510–1520 10.1056/NEJMoa1000931
    1. Jaspan HB, Berrisford AE, Boulle AM (2008) Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program. Pediatr Infect Dis J 27: 993–998 10.1097/INF.0b013e31817acf7b
    1. Estripeaut D, Mosser J, Doherty M, Acosta W, Shah H, et al. (2013) Mortality and long-term virologic outcomes in children and infants treated with lopinavir/ritonavir. Pediatr Infect Dis J 32: e466–472 10.1097/INF.0b013e3182a09276
    1. Alvarez-Uria G, Naik PK, Pakam R, Midde M (2012) Early HIV viral load determination after initiating first-line antiretroviral therapy for indentifying patients with high risk of developing virological failure: data from a cohort study in a resource-limited setting. Trop Med Int Health 17: 1152–1155 Available: . Accessed 2012 Sep 7.
    1. Arpadi S, Shiau S, Strehlau R, Martens L, Patel F, et al. (2013) Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. Arch Dis Child 98: 258–264 10.1136/archdischild-2012-302633
    1. Office of The Registrar General & Census Commissioner, India (2011) Census of India.
    1. Alvarez-Uria G, Midde M, Pakam R, Naik PK (2012) Gender differences, routes of transmission, socio-demographic characteristics and prevalence of HIV related infections of adults and children in an HIV cohort from a rural district of India. Infect Dis Rep 4: e19 10.4081/idr.2012.e19
    1. Alvarez-Uria G, Midde M, Pakam R, Kannan S, Bachu L, et al. (2012) Factors Associated with Late Presentation of HIV and Estimation of Antiretroviral Treatment Need according to CD4 Lymphocyte Count in a Resource-Limited Setting: Data from an HIV Cohort Study in India. Interdiscip Perspect Infect Dis 2012: 293795 10.1155/2012/293795
    1. Alvarez-Uria G, Midde M, Pakam R, Bachu L, Naik PK (2012) Effect of Formula Feeding and Breastfeeding on Child Growth, Infant Mortality, and HIV Transmission in Children Born to HIV-Infected Pregnant Women Who Received Triple Antiretroviral Therapy in a Resource-Limited Setting: Data from an HIV Cohort Study in India. ISRN Pediatr 2012: 763591 10.5402/2012/763591
    1. National AIDS Control Organisation (2006) Guidelines for HIV Care and Treatment in Infants and Children. Available: . Accessed 2013 Jul 31.
    1. Sáez-Llorens X, Violari A, Deetz CO, Rode RA, Gomez P, et al. (2003) Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J 22: 216–224 10.1097/01.inf.0000055061.97567.34
    1. Ramos J (2009) Boosted protease inhibitors as a therapeutic option in the treatment of HIV-infected children. HIV Med 10: 536–547 10.1111/j.1468-1293.2009.00728.x
    1. World Health Organization (2010) Antiretroviral therapy for HIV infection in infants and children: Towards universal access. Available: . Accessed 2011 Feb 10.
    1. PENTA Steering Committee (2009) Welch S, Sharland M, Lyall EGH, Tudor-Williams G, et al. (2009) PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 10: 591–613 10.1111/j.1468-1293.2009.00759.x
    1. World Health Organization (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Available: . Accessed 2013 Jul 20.
    1. Gang IN, Sen K, Yun MS (2002) Caste, Ethnicity, and Poverty in Rural India. IZA
    1. Alvarez-Uria G, Midde M, Naik PK (2012) Socio-demographic risk factors associated with HIV infection in patients seeking medical advice in a rural hospital of India. J Public health Res 1: e14 10.4081/jphr.2012.e14
    1. HIV Paediatric Prognostic Markers Collaborative Study (2010) Boyd K, Dunn DT, Castro H, Gibb DM, et al. (2010) Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children. AIDS 24: 1213–1217 10.1097/QAD.0b013e3283389f41
    1. HIV Paediatric Prognostic Markers Collaborative Study (2006) Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS 20: 1289–1294 10.1097/01.aids.0000232237.20792.68
    1. (n.d.). Available: . Accessed 2013 Aug 11.
    1. Royston P (2009) Multiple imputation of missing values: Further update of ice, with an emphasis on categorical variables. Stata Journal 9: 466–477.
    1. Ridgeway G, McCaffrey D, Morral A, Burgette L, Griffin BA (2013) Toolkit for Weighting and Analysis of Nonequivalent Groups: A tutorial for the twang package. R vignette RAND
    1. McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, et al. (2013) A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med 32: 3388–3414 10.1002/sim.5753
    1. Hill J (2004) Reducing bias in treatment effect estimation in observational studies suffering from missing data. Available: . Accessed 2 July 2014.
    1. Austin PC (2013) A tutorial on the use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 10.1002/sim.5984
    1. Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, et al. (2012) Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 366: 2380–2389 10.1056/NEJMoa1113249
    1. PENPACT-1 (PENTA 9/PACTG 390) Study Team (2011) Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, et al. (2011) First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis 11: 273–283 10.1016/S1473-3099(10)70313-3
    1. Kuhn L, Coovadia A, Strehlau R, Martens L, Hu C-C, et al. (2012) Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis 12: 521–530 10.1016/S1473-3099(12)70051-8
    1. UNITAID (n.d.) HIV/AIDS Diagnostics Technology Landscape 4th Edition. Available: .

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir